A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries. OBJECTIVE: The objective is to further investigate the relationship between SJS/TEN and HLA-B in a large number of patients in a European population. METHODS: HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN. We focused on patients related to 'high-risk' drugs including: 31 cases related to allopurinol, 28 to sulfamethoxazole, 19 to lamotrigine and 14 to oxicam. RESULTS: Sixty-one percent of 31 allopurinol-induced SJS/TEN patients carried the HLA-B*5801 allele and the figure was 55% for 27 patients of European ancestry [odds ratio=80 (34-187)], (P<10(-6)) as previously observed in Han Chinese. For other drugs, two rare alleles showed a weaker association with SJS/TEN in a limited number of patients: B*38 for sulfamethoxazole or lamotrigine-related patients, and B*73 for oxicam. CONCLUSION: At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“Adverse reactions to drugs are important causes of morbidity and even of death in developed countries [ 1 ].”
BackgroundA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380 · cited 1×
“In the previous years growing interest focused on the role of HLA in severe drug reactions, which was initiated by the demonstration that HLA-B*5701, was strongly associated with hypersensitivity to the anti-HIV medication abacavir [ 16 ,17].”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284 · cited 4×
“In Taiwan the carrier prevalence of B*5801 was 20% in a control group [ 21 ].”
BackgroundInfluentialMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005 · cited 1×
“The initial events triggering the immune reaction remain to be identified [ 10 ].”
BackgroundInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., Hu, S.-L., Wu, M.-T., Chen, G.-S., Wong, T.-W., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000199500.46842.4a · Cited by 680 · cited 2×
“The fact that B*1502 is a marker of SJS/TEN in Asia has now been confirmed in patients from countries other than Taiwan [ 22 ].”
BackgroundToxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells
Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M., & Roujeau, J.-C. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.07.047 · Cited by 412 · cited 2×
“From an immunological point of view it would make sense that recognition of drugs should be restricted by the MHC, especially class I antigen given the role of cytotoxic T-cells in cutaneous drug reactions [3, 15 ], but it is likely that other factors would also be implicated to explain the diversity in the final phen…”
BackgroundSelf-citationA marker for Stevens-Johnson syndrome …: ethnicity matters
Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M., et al. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500356 · Cited by 401
Self-citationRzany, B., Mockenhaupt, M., Baur, S., Schröder, W., Stocker, U., Mueller, J., Holländer, N., Bruppacher, R., & Schöpf, E. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00035-2 · Cited by 355
Self-citationApoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
PAUL, C., WOLKENSTEIN, P., ADLE, H., WECHSLER, J., GARCHON, H. J., REVUZ, J., & ROUJEAU, J. C. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb06976.x · Cited by 304 · cited 1×
“Patients develop an acute exanthema, which progresses towards limited (SJS) or widespread (TEN) blistering and erosion of the skin and mucous membranes, resulting from apoptosis of keratinocytes [ 4 ].”
BackgroundSelf-citationPharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?
Nebert, D. W. (1999) · Clinical Genetics · doi:10.1034/j.1399-0004.1999.560401.x · Cited by 272 · cited 1×
“Such defects could be genetically determined, as suggested by several examples of individual pharmacogenetic variability associated with specific adverse drug reactions [ 14 ].”
BackgroundSvensson, C. K., Cowen, E. W., & Gaspari, A. A. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01501-1 · Cited by 267
HLA-B Locus in Caucasian Patients with Carbamazepine hypersensitivity
Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., & Pirmohamed, M. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.813 · Cited by 264 · cited 1×
“Another report from the UK also suggested that this specific allele is not a marker of cutaneous reactions to carbamazepine in European patients [ 23 ].”
BackgroundNevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis
Fagot, J.-P., Mockenhaupt, M., Bouwes-Bavinck, J.-N., Naldi, L., Viboud, C., & Roujeau, J.-C. (2001) · AIDS · doi:10.1097/00002030-200109280-00014 · Cited by 200
Self-citationLife-threatening acute adverse cutaneous drug reactions
Wolf, R., Orion, E., Marcos, B., & Matz, H. (2005) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.06.012 · Cited by 175 · cited 1×
“retrospective studies [ 6 ], half of the cases are caused by a limited number of drugs: antibacterial sulfonamides, especially sulfamethoxazole (SMX), allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, NSAID of the oxicam type and nevirapine [7–9].”
BackgroundLe Cleach, L., Delaire, S., Boumsell, L., Bagot, M., Bourgault-Villada, I., Bensussan, A., & Roujeau, J. C. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2000.01119.x · Cited by 172
Self-citationKuhn, L., Coutsoudis, A., Moodley, D., Trabattoni, D., Mngqundaniso, N., Shearer, G. M., Clerici, M., Coovadia, H. M., & Stein, Z. (2001) · AIDS · doi:10.1097/00002030-200101050-00003 · Cited by 165
Functional Polymorphism of the KIR3DL1/S1 Receptor on Human NK Cells
O’Connor, G. M., Guinan, K. J., Cunningham, R. T., Middleton, D., Parham, P., & Gardiner, C. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.235 · Cited by 162
The complete primary structure of HLA-Bw58.
Ways, J. P., Coppin, H., & Parham, P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38967-6 · Cited by 89
HLA phenotypes and bullous cutaneous reactions to drugs
Roujeau, J., Bracq, C., Huyn, N. T., Chaussalet, E., Raffin, C., & Duedari, N. (1986) · Tissue Antigens · doi:10.1111/j.1399-0039.1986.tb00491.x · Cited by 71 · cited 1×
“Genetic susceptibility to SCARs has been suspected for years because of a few reports of family cases [11,12], and ancient studies suggesting weak associations with serologically determined HLA [ 13 ].”
ResultSelf-citationHigh prevalence of hyperuricemia in elderly Taiwanese.
Lee, M.-S., Lin, S., Chang, H.-Y., Lyu, L.-C., Tsai, K., & Pan, W.-H. (2005) · PubMed · Cited by 65
Familial occurrence of fixed drug eruptions.
Pellicano, R., Silvestris, A. M., Iannantuono, M., Ciavarella, G., & Lomuto, M. (1992) · Acta Dermato Venereologica · doi:10.2340/0001555572292293 · Cited by 20
Familial hypersensitivity to allopurinol with subsequent desensitization
Melsom, R. D. (1999) · Rheumatology · doi:10.1093/rheumatology/38.12.1301 · Cited by 16 · cited 1×
“Genetic susceptibility to SCARs has been suspected for years because of a few reports of family cases [ 11 ,12], and ancient studies suggesting weak associations with serologically determined HLA [13].”
Result
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Sassolas, B., Haddad, C., Mockenhaupt, M., Dunant, A., Liss, Y., Bork, K., Haustein, U. F., Vieluf, D., Roujeau, J. C., & Le Louet, H. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.252 · Cited by 758
Self-citationToxic epidermal necrolysis and Stevens-Johnson syndrome
Harr, T., & French, L. E. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-39 · Cited by 693
“This RegiSCAR study revealed that HLA-B*1502 is neither a marker for carbamazepine, sulfamethoxazole, lamotrigine, or NSAID’s of oxicam-type induced SJS/TEN nor a sufficient explanation for the cause of the disease in Europeans [35,36].”
Background
Metadata
- Authors
- Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J.-C., Hovnanian, A., & Mockenhaupt, M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Ben-Gurion University of the Negev (IL)
- University of Milan (IT)
- Leiden University Medical Center (NL)
- Innsbruck Medical University (AT)
- Université Paris-Est Créteil (FR)
- Corresponding author
- Roujeau, Jean-Claude
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025161685
- Cited by
- 624
- References
- 28
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 23 · 2019: 31 · 2018: 36 · 2017: 40 · 2016: 26 · 2015: 48 · 2014: 43 · 2013: 43 · 2012: 40
- FWCI
- 33.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Stevens-Johnson syndrome, toxic epidermal necrolysis, HLA-B*58:01, HLA-B*15:02, allopurinol, sulfamethoxazole, lamotrigine, oxicams, drug-induced skin reaction, European populations, genetic susceptibility
- MeSH terms
- Adult, Aged, Base Sequence, Female, Humans, Male, Middle Aged, Stevens-Johnson Syndrome, HLA-B Antigens, DNA Primers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.